Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
AnaptysBio
(NASDAQ:ANAB)
Intraday
$19.66
0
[0.00%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$19.66
0
[0.00%]
Last update: 4:00PM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for AnaptysBio Stock (NASDAQ:ANAB)
AnaptysBio Stock (NASDAQ: ANAB)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, April 16, 2024
Leerink Partners Initiates Coverage On AnaptysBio with Outperform Rating, Announces Price Target of $47
Benzinga Newsdesk
-
6 days ago
Thursday, April 11, 2024
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Apr 11, 2024, 1:33PM
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
-
Apr 11, 2024, 10:01AM
Wells Fargo Initiates Coverage On AnaptysBio with Overweight Rating, Announces Price Target of $56
Benzinga Newsdesk
-
Apr 11, 2024, 9:45AM
Monday, April 01, 2024
Unveiling 4 Analyst Insights On AnaptysBio
Benzinga Insights
-
Apr 1, 2024, 3:01PM
JP Morgan Maintains Neutral on AnaptysBio, Lowers Price Target to $28
Benzinga Newsdesk
-
Apr 1, 2024, 10:06AM
Tuesday, March 12, 2024
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
Vandana Singh
-
Mar 12, 2024, 2:48PM
AnaptysBio shares are trading higher after Wedbush upgraded the stock from Neutral to Outperform.
Benzinga Newsdesk
-
Mar 12, 2024, 12:19PM
Wedbush Upgrades AnaptysBio to Outperform
Benzinga Newsdesk
-
Mar 12, 2024, 7:11AM
Monday, March 11, 2024
AnaptysBio Q4 EPS $(1.59) Beats $(1.60) Estimate, Sales $9.01M Beat $2.23M Estimate
Happy Mohamed
-
Mar 11, 2024, 4:29PM
Monday, February 26, 2024
BTIG Initiates Coverage On AnaptysBio with Buy Rating, Announces Price Target of $55
Benzinga Newsdesk
-
Feb 26, 2024, 7:34AM
Wednesday, February 21, 2024
Stifel Initiates Coverage On AnaptysBio with Buy Rating, Announces Price Target of $50
Benzinga Newsdesk
-
Feb 21, 2024, 5:43AM
Friday, January 05, 2024
AnaptysBio Inc Expects To Report That It Had Cash And Cash Equivalents And Investments Of ~$417M As Of December 31, 2023
Benzinga Newsdesk
-
Jan 5, 2024, 4:20PM
Wednesday, November 29, 2023
Wedbush Reiterates Neutral on AnaptysBio, Maintains $20 Price Target
Benzinga Newsdesk
-
Nov 29, 2023, 8:21AM
Monday, November 27, 2023
Anaptys Expands Immune Cell Modulator Pipeline With Exclusive License To BDCA2 Modulator Antibody Portfolio From Centessa Pharmaceuticals; Anaptys Will Pay Centessa A One-Time Upfront Cash Payment Of $7M
Benzinga Newsdesk
-
Nov 27, 2023, 4:16PM
Friday, November 03, 2023
Wedbush Maintains Neutral on AnaptysBio, Raises Price Target to $20
Benzinga Newsdesk
-
Nov 3, 2023, 9:56AM
Thursday, November 02, 2023
AnaptysBio Q3 EPS $(1.41) Beats $(1.79) Estimate, Sales $3.32M Beat $2.51M Estimate
Benzinga Newsdesk
-
Nov 2, 2023, 5:31PM
Wednesday, November 01, 2023
UBS Maintains Neutral on AnaptysBio, Lowers Price Target to $21
Benzinga Newsdesk
-
Nov 1, 2023, 2:55PM
Wednesday, October 11, 2023
AnaptysBio To Present Phase 1 Data On ANB032, Its BTLA Agonist Antibody, At The 32nd EADV Congress
Benzinga Newsdesk
-
Oct 11, 2023, 9:16AM
Monday, October 09, 2023
Why Is Skin Disease Focused AnaptysBio Stock Trading Higher Today?
Vandana Singh
-
Oct 9, 2023, 9:26AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Oct 9, 2023, 9:06AM
Market-Moving News for October 9th
Benzinga Newsdesk
-
Oct 9, 2023, 8:54AM
AnaptysBio shares are trading higher after the company announced imsidolimab met the primary endpoint of its global Phase 3 GEMINI-1 trial, achieving rapid clearance of GPP through Week 4 after a single dose.
Benzinga Newsdesk
-
Oct 9, 2023, 8:40AM
AnaptysBio Shares Resume Trade
Benzinga Newsdesk
-
Oct 9, 2023, 8:35AM
Anaptys To Provide Overview Of Rosnilimab, A PD-1 Agonist, At Virtual R&D Event On Wednesday, Oct. 25
Benzinga Newsdesk
-
Oct 9, 2023, 8:19AM
AnaptysBio, Inc. Shares To Resume Trade At 8:30 a.m. ET
Benzinga Newsdesk
-
Oct 9, 2023, 8:03AM
Anaptys Announces Top-Line Phase 3 Clinical Trial Results Of Imsidolimab In Generalized Pustular Psoriasis
Benzinga Newsdesk
-
Oct 9, 2023, 8:01AM
AnaptsysBio Trading Halt: Halt News Pending
Charles Gross
-
Oct 9, 2023, 7:59AM
Tuesday, September 19, 2023
Board Member at AnaptysBio Acquires Company Stock Options Worth 13,911 Shares
Benzinga Insights
-
Sep 19, 2023, 11:00AM
Monday, September 18, 2023
AnaptysBio Appoints John Orwin As Chairman Of Board; Jamie Topper Is Stepping Down And Will Serve As An Advisor To Board Through Q1 2024
Benzinga Newsdesk
-
Sep 18, 2023, 4:16PM
Tuesday, August 08, 2023
Wedbush Maintains Neutral on AnaptysBio, Lowers Price Target to $26
Benzinga Newsdesk
-
Aug 8, 2023, 8:40AM
Monday, July 31, 2023
Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session
Lisa Levin
-
Jul 31, 2023, 3:30PM
AnaptysBio- And GSK-Partnered Immuno-Oncology Agent JEMPERLI Plus Chemotherapy Approved In The U.S. For dMMR/MSI-H Primary Advanced Or Recurrent Endometrial Cancer
Happy Mohamed
-
Jul 31, 2023, 1:37PM
Monday, July 24, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Jul 24, 2023, 3:48PM
Friday, July 21, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Jul 21, 2023, 1:24PM
Monday, May 22, 2023
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
Benzinga Insights
-
May 22, 2023, 11:00AM
JP Morgan Upgrades AnaptysBio to Neutral, Lowers Price Target to $30
Benzinga Newsdesk
-
May 22, 2023, 5:08AM
Friday, May 12, 2023
Wedbush Reiterates Neutral on AnaptysBio, Maintains $29 Price Target
Benzinga Newsdesk
-
May 12, 2023, 9:48AM
Guggenheim Maintains Buy on AnaptysBio, Raises Price Target to $45
Benzinga Newsdesk
-
May 12, 2023, 6:59AM
Thursday, May 11, 2023
AnaptysBio Q1 EPS $(1.58) Misses $(1.04) Estimate, Sales $1.37M Miss $2.22M Estimate
Happy Mohamed
-
May 11, 2023, 4:46PM
Tuesday, May 02, 2023
AnaptysBio Announces British Journal Of Dermatology Publication Of Imsidolimab Previously Reported Phase 2 GALLOP Data In Generalized Pustular Psoriasis
Happy Mohamed
-
May 2, 2023, 9:17AM
Wednesday, April 12, 2023
JP Morgan Maintains Underweight on AnaptysBio, Lowers Price Target to $31
Benzinga Newsdesk
-
Apr 12, 2023, 9:39AM
Tuesday, March 28, 2023
GSK Unveils Detailed Phase 3 Data For Jemperli In Frontline Endometrial Cancer Patients
Vandana Singh
-
Mar 28, 2023, 12:04PM
Reported Late Monday March 27, AnaptysBio And GSK Partnered Immuno-Oncology Agent Jemperli Plus Chemotherapy Demonstrates Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival For The Treatment Of Primary Advanced Or Recurrent Endometrial Cancer Versus Chemotherapy Alone In Phase 3 Ruby Trial
Happy Mohamed
-
Mar 28, 2023, 12:59AM
Wednesday, March 01, 2023
AnaptysBio Q4 EPS $(0.93) Beats $(0.97) Estimate, Sales $6.81M Miss $6.83M Estimate
Happy Mohamed
-
Mar 1, 2023, 4:52PM
Friday, January 13, 2023
AnaptysBio Announces Stock Repurchase Plan Of Up To $50M Of The Company's Outstanding Common Stock
Benzinga Newsdesk
-
Jan 13, 2023, 9:01AM
Friday, January 06, 2023
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Jan 6, 2023, 1:16PM
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Jan 6, 2023, 12:30PM
Greenbrier, Fate Therapeutics, AnaptysBio And Some Other Big Stocks Moving Lower On Friday
Lisa Levin
-
Jan 6, 2023, 11:17AM
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Benzinga Insights
-
Jan 6, 2023, 10:00AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch